Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 7/20 | 0.69 |
| ▸ | FGF2 | P09038 | 5/20 | 0.69 |
| ▸ | HPSE | Q9Y251 | 14/20 | 0.54 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.49 |
| ▸ | VEGFA | P15692 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904646 | 0.94 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL4906384 | 0.94 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020073 | 0.94 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL2528200 | 0.93 | FGF1 (0.62) | FGF1FGF2HPSESERPINC1 | |
| SCHEMBL2524663 | 0.93 | FGF1 (0.62) | FGF1FGF2HPSESERPINC1 | |
| SCHEMBL18742104 | 0.92 | FGF1 (0.76) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL18742103 | 0.92 | FGF1 (0.76) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL7311357 | 0.92 | FGF1 (0.76) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020078 | 0.88 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020081 | 0.88 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215717-A1 | Sulfated oligosaccharides | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2009-08-27 | — | — | US | claimed |
| WO-2006017752-A2 | SULFATED OLIGOSACCHARIDES | IVAX CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-10299714-B2 | Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide | BECTON, DICKINSON AND COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2645932-B1 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | BECTON DICKINSON CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2645932-A2 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | Becton, Dickinson and Company (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20120149004-A1 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | BECTON, DICKINSON AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012075407-A2 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | BECTON, DICKINSON AND COMPANY (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20090215717-A1 | Sulfated oligosaccharides | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2009-08-27 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
| EP-0230023-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ENHANCEMENT OF WOUND HEALING | MARION MERRELL DOW INC. (US) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149004-A1 | BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT | FUCA2, HBG1, FUT6 | FGF1 1162/4885FGF2 476/4885HPSE 18/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FGF1 358/4885FGF2 230/4885HPSE 1/4885 |
| US-20090215717-A1 | Sulfated oligosaccharides | CSGALNACT1, ST3GAL3, ALG1 | FGF1 485/4885FGF2 229/4885HPSE 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.